Open Monoclonal Technology, WuXi PharmaTech deal

Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.) said it will receive $4 million in combined payments under two separate deals granting access to its OmniAb antibody discovery platform. New WuXi Life Science Ltd. (Shanghai, China) sublicensed Chinese rights to an undisclosed company an antibody WuXi discovered using OmniAb under a 2012 deal. The sublicense triggered a payment to Ligand. The original deal was between OMT, which Ligand acquired, and WuXi PharmaTech, which New WuXi acquired. ...